<DOC>
	<DOCNO>NCT01663857</DOCNO>
	<brief_summary>A study woman ovarian cancer return least 6 month platinum-based chemotherapy .</brief_summary>
	<brief_title>A Study LY2228820 Recurrent Ovarian Cancer</brief_title>
	<detailed_description>Phase 1b unblinded small number participant take LY2228820 plus gemcitabine carboplatin test safety combination determine recommend dose Phase 2 portion . Phase 2 blind study participant receive carboplatin gemcitabine . Participants one group receive LY2228820 , group receive placebo . If participant achieves least stable disease , maintenance phase follow first 6 cycle . The participant take either LY2228820 placebo . The participant continue therapy disease progression discontinuation criterion fulfil .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Have diagnose ovarian , fallopian tube , primary peritoneal cancer Have treat one time platinumbased chemotherapy disease come back least six month complete treatment Are able swallow tablet Have give write informed consent prior study procedure Have adequate blood count , hepatic renal function Have performance status equal le 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have negative pregnancy test , participant child bear potential must use birth control study three month stop study drug Have previously treat Gemcitabine ovarian , fallopian tube primary peritoneal cancer Are currently enrol discontinue less 14 day another clinical trial Have history inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) Have take certain medication grapefruit juice within 7 day initial dose study drug , level study drug may affect . Must pregnant breastfeeding . Have malignancy metastasis central nervous system Have borderline malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>